Hepatic impairment: Starting dose

  • Because the exposure and toxicity of paclitaxel can be increased with hepatic impairment, administration of ABRAXANE in patients with hepatic impairment should be performed with caution
  • Patients with hepatic impairment may have a higher risk of toxicity, particularly from myelosuppression. Monitor these patients closely
  • Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
  • No dose adjustment is necessary for patients with mild hepatic impairment
  • Patient with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
  • Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance

Hepatic Impairment (Make a selection)

  • Mild
  • Moderate
  • Severe
  • Very Severe
ABRAXANE bottle

Illustrative purposes only.

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >ULN to ?1.5 x ULN
ABRAXANE bottle

Illustrative purposes only.

aA dose increase to 100 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles.

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >1.5 to ≤3 x ULN
ABRAXANE bottle

Illustrative purposes only.

aA dose increase to 100 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles.

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >3 to ≤5 x ULN
Metastatic breast cancer dose adjustments for hepatic impairment

Illustrative purposes only.

SGOT (AST) Levels >10 x ULN
OR
Bilirubin Levels >5 x ULN
ULN=upper limit of normal.

Hepatic impairment: Starting dose

Hepatic Impairment (Make a selection)

  • Mild
  • Moderate
  • Severe
  • Very Severe
ABRAXANE bottle
ABRAXANE bottle
MBC dose adjustments for hepatic impairment
Metastatic breast cancer dose adjustments for hepatic impairment

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.